Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 208

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 208
---
. These included a presentation on succession planning for criticalroles, with a particular focus on R&D.                                                                                                                             |

| 102 | SANOFIFORM 20-F2024 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

Evaluation of the Board and its Committees in 2024 - Internal evaluation with assistance from an independent consultant In 2024 there was a formal evaluation under the direction of the Appointments, Governance and CSR Committee, with assistance from an independent consultancy firm. The evaluation, which took several weeks, was conducted as follows: • issuance of a questionnaire to all directors, the main topics addressed being: alignment of the composition of the Board with Sanofi's requirements; quality of documentation and presentations; working practices; usefulness of resources provided to the Board and its committees; compliance of corporate governance with best practice; quality of debates and freedom of expression; composition and remit of committees; relations between the Board and the Executive Committee, shareholders and stakeholders; directors' expectations; personal contributions, including by the Chairman competencies and effective participation in debate; • review of responses received from the directors; and • individual interviews conducted by the selected consultant. In addition, all along 2024, the Chairman of the Board conducted discussions with each director intended to measure their contribution to the work of the Board and its committees and to record any suggestions they may have. The results of the 2024 evaluation were presented and discussed at a meeting of the Appointments, Governance and CSR Committee on February 4, 2025, and the detail report finalized at that meeting was presented to the Sanofi Board of Directors on February 12, 2025. Overall, the board members considered that the functioning of the board improved in 2024 and that the board has been able to conduct a robust decision-making process on key strategic projects, while having more open and collegial interactions. The board demonstrated an increased capacity to work together and sustain a very dense agenda over the last months. The structure of the agendas and the time allocation to each topic are considered as adequate. The development of the board as a team has been enhanced by the visit to China. The composition and the size of the board are considered as appropriate with the right level of diversity of all kinds, especially with regards to nationalities, gender and expertise. The recent changes contributed to increase the expertise in the pharma sector, in particular in the areas of therapeutic focus of the company. In terms of evolution of the board’s composition, strengthening skills in that domain